# Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer

> **NCT00003023** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Neuroblastoma
- Sarcoma

## Interventions

- **BIOLOGICAL:** BCG vaccine
- **BIOLOGICAL:** monoclonal antibody A1G4 anti-idiotype vaccine

## Key facts

- **NCT ID:** NCT00003023
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-03
- **Primary completion:** 2005-01
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2013-01-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003023, "Monoclonal Antibody A1G4 Plus BCG in Treating Patients With Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00003023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*